Faculty, Staff and Student Publications

Publication Date

1-1-2024

Journal

Frontiers in Pharmacology

DOI

10.3389/fphar.2024.1291212

PMID

38379905

PMCID

PMC10876831

PubMedCentral® Posted Date

2-6-2024

PubMedCentral® Full Text Version

Post-print

Abstract

Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants

Keywords

COVID-19, COVID-19 and anti-viral agents, Coronavirus, TQ formula, Thymoquinone TQ, fatty acids

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.